Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade
March 15, 2018 at 13:12 PM EDT
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|